RPS6KA3 and lung carcinoma: BI-D1870, U0126 and each targeted tyrosine kinase inhibitor, including gefitinib and crizotinib, abrogated pS-EphA2, indicating that the RSK–EphA2 axis was constitutively activated by driver oncogene products in all these lung cancer cells (Fig. 6c).